{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T19:15:32Z","timestamp":1790795732790,"version":"4.1.0"},"reference-count":45,"publisher":"PeerJ","license":[{"start":{"date-parts":[[2024,5,30]],"date-time":"2024-05-30T00:00:00Z","timestamp":1717027200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Project of Wenzhou Municipal Science and Technology Bureau","award":["Y20220192"],"award-info":[{"award-number":["Y20220192"]}]},{"DOI":"10.13039\/501100001809","name":"The National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["81973397"],"award-info":[{"award-number":["81973397"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"The National Key Research and Development Program of China","award":["2020YFC2008301"],"award-info":[{"award-number":["2020YFC2008301"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:sec>\n               <jats:title>Objectives<\/jats:title>\n               <jats:p>To investigate the interaction between tramadol and representative tyrosine kinase inhibitors, and to study the inhibition mode of drug-interaction.<\/jats:p>\n            <\/jats:sec>\n            <jats:sec>\n               <jats:title>Methods<\/jats:title>\n               <jats:p>Liver microsomal catalyzing assay was developed. Sprague-Dawley rats were administrated tramadol with or without selected tyrosine kinase inhibitors. Samples were prepared and ultra-performance liquid chromatography\u2013tandem mass spectrometry (UPLC-MS\/MS) was used for analysis. Besides, liver, kidney, and small intestine were collected and morphology was examined by hematoxyline-eosin (H&amp;E) staining. Meanwhile, liver microsomes were prepared and carbon monoxide differential ultraviolet radiation (UV) spectrophotometric quantification was performed.<\/jats:p>\n            <\/jats:sec>\n            <jats:sec>\n               <jats:title>Results<\/jats:title>\n               <jats:p>Among the screened inhibitors, crizotinib takes the highest potency in suppressing the metabolism of tramadol in rat\/human liver microsome, following non-competitive inhibitory mechanism. <jats:italic>In vivo<\/jats:italic>, when crizotinib was co-administered, the AUC value of tramadol increased compared with the control group. Besides, no obvious pathological changes were observed, including cell morphology, size, arrangement, nuclear morphology with the levels of alanine transaminase (ALT) and aspartate transaminase (AST) increased after multiple administration of crizotinib. Meanwhile, the activities of CYP2D1 and CYP3A2 as well as the total cytochrome P450 abundance were found to be decreased in rat liver of combinational group.<\/jats:p>\n            <\/jats:sec>\n            <jats:sec>\n               <jats:title>Conclusions<\/jats:title>\n               <jats:p>Crizotinib can inhibit the metabolism of tramadol. Therefore, this recipe should be vigilant to prevent adverse reactions.<\/jats:p>\n            <\/jats:sec>","DOI":"10.7717\/peerj.17446","type":"journal-article","created":{"date-parts":[[2024,5,30]],"date-time":"2024-05-30T09:45:22Z","timestamp":1717062322000},"page":"e17446","source":"Crossref","is-referenced-by-count":1,"title":["Crizotinib inhibits the metabolism of tramadol by non-competitive suppressing the activities of CYP2D1 and CYP3A2"],"prefix":"10.7717","volume":"12","author":[{"given":"Nanyong","family":"Gao","sequence":"first","affiliation":[{"name":"Yueqing Maternity and Child Health Hospital, Wenzhou, China"},{"name":"Wenzhou Medical University, Wenzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyu","family":"Xu","sequence":"additional","affiliation":[{"name":"Wenzhou Medical University, Wenzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Ye","sequence":"additional","affiliation":[{"name":"Wenzhou Medical University, Wenzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin-yue","family":"Li","sequence":"additional","affiliation":[{"name":"Wenzhou Medical University, Wenzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengqi","family":"Lin","sequence":"additional","affiliation":[{"name":"Wannan Medical College, Wu hu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiu-wei","family":"Shen","sequence":"additional","affiliation":[{"name":"Ruian People\u2019s Hospital, Wenzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianchang","family":"Qian","sequence":"additional","affiliation":[{"name":"Wenzhou Medical University, Wenzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"4443","published-online":{"date-parts":[[2024,5,30]]},"reference":[{"key":"10.7717\/peerj.17446\/ref-1","doi-asserted-by":"publisher","first-page":"e0214598","DOI":"10.1371\/journal.pone.0214598","article-title":"Validated LC-MS\/MS assay for quantification of the newly approved tyrosine kinase inhibitor, dacomitinib, and application to investigating its metabolic stability","volume":"14","author":"Abdelhameed","year":"2019","journal-title":"PLOS ONE"},{"key":"10.7717\/peerj.17446\/ref-2","doi-asserted-by":"publisher","first-page":"114171","DOI":"10.1016\/j.jpba.2021.114171","article-title":"Simultaneous LC-MS\/MS quantification of oxycodone, tramadol and fentanyl and their metabolites (noroxycodone, oxymorphone, O- desmethyltramadol, N-desmethyltramadol, and norfentanyl) in human plasma and whole blood collected via venepuncture and volumetric absorptive micro sampling","volume":"203","author":"Al-Qurain","year":"2021","journal-title":"Journal of Pharmaceutical and Biomedical Analysis"},{"key":"10.7717\/peerj.17446\/ref-3","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1007\/s40262-014-0191-9","article-title":"Tramadol and O-desmethyl tramadol clearance maturation and disposition in humans: a pooled pharmacokinetic study","volume":"54","author":"Allegaert","year":"2015","journal-title":"Clinical Pharmacokinetics"},{"key":"10.7717\/peerj.17446\/ref-4","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1080\/03602532.2016.1229788","article-title":"Comparative metabolism of tramadol and tapentadol: a toxicological perspective","volume":"48","author":"Barbosa","year":"2016","journal-title":"Drug Metabolism Reviews"},{"key":"10.7717\/peerj.17446\/ref-5","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1097\/CM9.0000000000001474","article-title":"Changing profiles of cancer burden worldwide and in China: a secondary analysis of the global cancer statistics 2020","volume":"134","author":"Cao","year":"2021","journal-title":"Chinese Medical Journal"},{"key":"10.7717\/peerj.17446\/ref-6","doi-asserted-by":"publisher","first-page":"1512","DOI":"10.3390\/cancers14061512","article-title":"Early on-treatment prediction of the mechanisms of acquired resistance to EGFR tyrosine kinase inhibitors","volume":"14","author":"Choi","year":"2022","journal-title":"Cancers"},{"key":"10.7717\/peerj.17446\/ref-7","doi-asserted-by":"publisher","first-page":"2177","DOI":"10.3390\/pharmaceutics14102177","article-title":"An investigation of O-Demethyl Tramadol\/Tramadol ratio for cytochrome P450 2D6 phenotyping: the CYTRAM study","volume":"14","author":"De La Gastine","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.7717\/peerj.17446\/ref-8","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1124\/dmd.112.050310","article-title":"Metabolism and pharmacokinetics of novel selective vascular endothelial growth factor receptor-2 inhibitor apatinib in humans","volume":"41","author":"Ding","year":"2013","journal-title":"Drug Metabolism And Disposition"},{"key":"10.7717\/peerj.17446\/ref-9","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1186\/s12890-020-01390-6","article-title":"Successful treatment with alectinib after crizotinib-induced hepatitis in ALK-rearranged advanced lung cancer patient: a case report","volume":"21","author":"Duarte","year":"2021","journal-title":"BMC Pulmonary Medicine"},{"key":"10.7717\/peerj.17446\/ref-10","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1097\/01.JTO.0000263712.61697.69","article-title":"Phase II study of gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), and celecoxib, a cyclooxygenase-2 (COX-2) inhibitor, in patients with platinum refractory non-small cell lung cancer (NSCLC)","volume":"2","author":"Gadgeel","year":"2007","journal-title":"Journal of Thoracic Oncology"},{"key":"10.7717\/peerj.17446\/ref-11","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1007\/s002100000266","article-title":"Affinity, potency and efficacy of tramadol and its metabolites at the cloned human mu-opioid receptor","volume":"362","author":"Gillen","year":"2000","journal-title":"Naunyn-Schmiedeberg\u2019s Archives of Pharmacology"},{"key":"10.7717\/peerj.17446\/ref-12","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1097\/FPC.0000000000000057","article-title":"PharmGKB summary: tramadol pathway","volume":"24","author":"Gong","year":"2014","journal-title":"Pharmacogenet Genomics"},{"key":"10.7717\/peerj.17446\/ref-13","doi-asserted-by":"publisher","first-page":"879","DOI":"10.2165\/00003088-200443130-00004","article-title":"Clinical pharmacology of tramadol","volume":"43","author":"Grond","year":"2004","journal-title":"Clinical Pharmacokinetics"},{"key":"10.7717\/peerj.17446\/ref-14","doi-asserted-by":"publisher","first-page":"2857","DOI":"10.1111\/bph.13809","article-title":"Targeting multiple opioid receptors\u2014improved analgesics with reduced side effects?","volume":"175","author":"G\u00fcnther","year":"2018","journal-title":"British Journal of Pharmacology"},{"key":"10.7717\/peerj.17446\/ref-15","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/j.jep.2013.10.021","article-title":"Marsdenia tenacissima extract inhibits gefitinib metabolism in vitro by interfering with human hepatic CYP3A4 and CYP2D6 enzymes","volume":"151","author":"Han","year":"2014","journal-title":"Journal of Ethnopharmacology"},{"key":"10.7717\/peerj.17446\/ref-16","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1111\/1759-7714.13825","article-title":"Crizotinib for recurring non-small-cell lung cancer with EML4-ALK fusion genes previously treated with alectinib: a phase II trial","volume":"12","author":"Harada","year":"2021","journal-title":"Thorac Cancer"},{"key":"10.7717\/peerj.17446\/ref-17","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1515\/dmpt-2017-0018","article-title":"Evaluation of the Ecstasy influence on tramadol and its main metabolite plasma concentration in rats","volume":"32","author":"Jamali","year":"2017","journal-title":"Drug Metabolism and Personalized Therapy"},{"key":"10.7717\/peerj.17446\/ref-18","doi-asserted-by":"publisher","first-page":"121844","DOI":"10.1016\/j.jchromb.2019.121844","article-title":"A simple and fast LC-MS\/MS method for the routine measurement of cabozantinib, olaparib, palbociclib, pazopanib, sorafenib, sunitinib and its main active metabolite in human plasma","volume":"1132","author":"Jolibois","year":"2019","journal-title":"Journal of chromatography. B, Analytical Technologies in the Biomedical and Life Sciences"},{"key":"10.7717\/peerj.17446\/ref-19","doi-asserted-by":"publisher","first-page":"e54","DOI":"10.1111\/jvp.12424","article-title":"The effects of ketoconazole and cimetidine on the pharmacokinetics of oral tramadol in greyhound dogs","volume":"40","author":"KuKanich","year":"2017","journal-title":"Journal of Veterinary Pharmacology and Therapeutics"},{"key":"10.7717\/peerj.17446\/ref-20","doi-asserted-by":"publisher","first-page":"785865","DOI":"10.3389\/fonc.2022.785865","article-title":"Outcomes of anlotinib maintenance therapy in patients with advanced NSCLC in a real-world setting","volume":"12","author":"Li","year":"2022","journal-title":"Frontiers in Oncology"},{"key":"10.7717\/peerj.17446\/ref-21","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1016\/j.jclinepi.2012.12.018","article-title":"Time from (clinical or certainty) diagnosis to treatment onset in cancer patients: the choice of diagnostic date strongly influences differences in therapeutic delay by tumor site and stage","volume":"66","author":"Macia","year":"2013","journal-title":"Journal of Clinical Epidemiology"},{"key":"10.7717\/peerj.17446\/ref-22","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1124\/dmd.112.049114","article-title":"Prediction of crizotinib-midazolam interaction using the Simcyp population-based simulator: comparison of CYP3A time-dependent inhibition between human liver microsomes versus hepatocytes","volume":"41","author":"Mao","year":"2013","journal-title":"Drug Metabolism and Disposition"},{"key":"10.7717\/peerj.17446\/ref-23","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1093\/oncolo\/oyab081","article-title":"Methadone as first-line opioid for the management of cancer pain","volume":"27","author":"Mercadante","year":"2022","journal-title":"Oncologist"},{"key":"10.7717\/peerj.17446\/ref-24","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1213\/ANE.0000000000001683","article-title":"Trends in tramadol: pharmacology, metabolism, and misuse","volume":"124","author":"Miotto","year":"2017","journal-title":"Anesthesia & Analgesia"},{"key":"10.7717\/peerj.17446\/ref-25","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1186\/s12893-021-01305-0","article-title":"Individualization of risk factors for postoperative complication after lung cancer surgery: a retrospective study","volume":"21","author":"Motono","year":"2021","journal-title":"BMC Surgery"},{"issue":"23","key":"10.7717\/peerj.17446\/ref-26","doi-asserted-by":"publisher","first-page":"4422","DOI":"10.1002\/cam4.4789","article-title":"Association of anticoagulant use with clinical outcomes from crizotinib in ALK- and ROS1-rearranged advanced non-small cell lung cancers: a retrospective analysis of PROFILE 1001","volume":"1","author":"Ng","year":"2022","journal-title":"Cancer Medicine"},{"key":"10.7717\/peerj.17446\/ref-27","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1345\/aph.1R002","article-title":"Crizotinib: a new treatment option for ALK-positive non-small cell lung cancer","volume":"47","author":"O\u2019Bryant","year":"2013","journal-title":"Annals of Pharmacotherapy"},{"key":"10.7717\/peerj.17446\/ref-28","doi-asserted-by":"publisher","first-page":"1963","DOI":"10.1124\/dmd.116.071902","article-title":"Tramadol metabolism to O-desmethyl tramadol (M1) and N-desmethyl tramadol (M2) by dog liver microsomes: Species comparison and identification of responsible canine cytochrome P-450s (CYPs)","volume":"44","author":"Perez Jimenez","year":"2016","journal-title":"Drug Metabolism and Disposition"},{"key":"10.7717\/peerj.17446\/ref-29","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1007\/s00228-014-1799-2","article-title":"Effects of terbinafine and itraconazole on the pharmacokinetics of orally administered tramadol","volume":"71","author":"Saarikoski","year":"2015","journal-title":"European Journal of Clinical Pharmacology"},{"key":"10.7717\/peerj.17446\/ref-30","doi-asserted-by":"publisher","first-page":"554","DOI":"10.4103\/0970-9185.222512","article-title":"Tramadol-induced hypoglycemia: an unusual adverse effect","volume":"33","author":"Senthilkumaran","year":"2017","journal-title":"Journal of Anaesthesiology Clinical Pharmacology"},{"key":"10.7717\/peerj.17446\/ref-31","doi-asserted-by":"publisher","first-page":"2018","DOI":"10.1056\/NEJMoa2027187","article-title":"First-line lorlatinib or crizotinib in advanced ALK-positive lung cancer","volume":"383","author":"Shaw","year":"2020","journal-title":"The New England Journal of Medicine"},{"key":"10.7717\/peerj.17446\/ref-32","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1007\/s00520-014-2415-9","article-title":"Use of non-opioid analgesics as adjuvants to opioid analgesia for cancer pain management in an inpatient palliative unit: does this improve pain control and reduce opioid requirements?","volume":"23","author":"Shinde","year":"2014","journal-title":"Supportive Care in Cancer"},{"key":"10.7717\/peerj.17446\/ref-33","doi-asserted-by":"publisher","first-page":"pdb.prot5455","DOI":"10.1101\/pdb.prot5455","article-title":"Homogenization of mammalian tissue","volume":"2010","author":"Simpson","year":"2010","journal-title":"Cold Spring Harbor Protocols"},{"key":"10.7717\/peerj.17446\/ref-34","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"Cancer Journal for Clinicians"},{"key":"10.7717\/peerj.17446\/ref-35","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1016\/j.pharep.2017.01.027","article-title":"The influence of a single and chronic administration of venlafaxine on tramadol pharmacokinetics in a rabbit model","volume":"69","author":"Szkutnik-Fiedler","year":"2017","journal-title":"Pharmacological Reports"},{"key":"10.7717\/peerj.17446\/ref-36","doi-asserted-by":"publisher","first-page":"943","DOI":"10.2146\/ajhp120261","article-title":"Crizotinib for the treatment of non-small-cell lung cancer","volume":"70","author":"Timm","year":"2013","journal-title":"American Journal of Health-System Pharmacy"},{"key":"10.7717\/peerj.17446\/ref-37","doi-asserted-by":"publisher","first-page":"3185","DOI":"10.2169\/internalmedicine.54.4996","article-title":"Alternate-day treatment with crizotinib for drug-induced esophagitis and liver damage in a patient with EML4-ALK fusion gene-positive lung adenocarcinoma","volume":"54","author":"Tsukita","year":"2015","journal-title":"Internal Medicine"},{"key":"10.7717\/peerj.17446\/ref-38","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.lungcan.2015.12.010","article-title":"Crizotinib-induced fatal fulminant liver failure","volume":"93","author":"Van Geel","year":"2016","journal-title":"Lung Cancer"},{"issue":"24","key":"10.7717\/peerj.17446\/ref-39","doi-asserted-by":"publisher","first-page":"7451","DOI":"10.3390\/jcm11247451","article-title":"New perspectives on the adverse effects of NSAIDs in cancer pain: an Italian Delphi study from the Rational Use of Analgesics (RUA) group","volume":"11","author":"Varrassi","year":"2022","journal-title":"Journal of Clinical Medicine"},{"key":"10.7717\/peerj.17446\/ref-40","doi-asserted-by":"publisher","first-page":"97","DOI":"10.2174\/1874467210666170704110146","article-title":"Opioids in the frame of new psychoactive substances network: a complex pharmacological and toxicological issue","volume":"11","author":"Ventura","year":"2018","journal-title":"Current Molecular Pharmacology"},{"key":"10.7717\/peerj.17446\/ref-41","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1080\/00498250110057378","article-title":"Metabolism of the analgesic drug, tramadol hydrochloride, in rat and dog","volume":"31","author":"Wu","year":"2001","journal-title":"Xenobiotica"},{"key":"10.7717\/peerj.17446\/ref-42","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1002\/jcph.356","article-title":"Evaluation of crizotinib absolute bioavailability, the bioequivalence of three oral formulations, and the effect of food on crizotinib pharmacokinetics in healthy subjects","volume":"55","author":"Xu","year":"2015","journal-title":"The Journal of Clinical Pharmacology"},{"key":"10.7717\/peerj.17446\/ref-43","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/j.soncn.2019.04.011","article-title":"Genetic variants associated with cancer pain and response to opioid analgesics: implications for precision pain management","volume":"35","author":"Yang","year":"2019","journal-title":"Seminars in Oncology Nursing"},{"key":"10.7717\/peerj.17446\/ref-44","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1080\/10550887.2012.665728","article-title":"Tramadol versus methadone for treatment of opiate withdrawal: a double-blind, randomized, clinical trial","volume":"31","author":"Zarghami","year":"2012","journal-title":"Journal of Addictive Diseases"},{"key":"10.7717\/peerj.17446\/ref-45","doi-asserted-by":"publisher","first-page":"1668","DOI":"10.18632\/oncotarget.13774","article-title":"Suppression of immune regulatory cells with combined therapy of celecoxib and sunitinib in renal cell carcinoma","volume":"8","author":"Zhao","year":"2017","journal-title":"Oncotarget"}],"container-title":["PeerJ"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/peerj.com\/articles\/17446.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/peerj.com\/articles\/17446.xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/peerj.com\/articles\/17446.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/peerj.com\/articles\/17446.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,30]],"date-time":"2024-05-30T09:45:32Z","timestamp":1717062332000},"score":1,"resource":{"primary":{"URL":"https:\/\/peerj.com\/articles\/17446"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,30]]},"references-count":45,"alternative-id":["10.7717\/peerj.17446"],"URL":"https:\/\/doi.org\/10.7717\/peerj.17446","archive":["CLOCKSS","LOCKSS","Portico"],"relation":{},"ISSN":["2167-8359"],"issn-type":[{"value":"2167-8359","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,30]]},"article-number":"e17446"}}